called Saxenda. “There are many people on this drug, and they will benefit by another generic version of it,” Dr. Harlan Krumholz, a cardiologist at Yale University and Yale New Haven Hospital ...

"Saxenda has the potential to help some of these ... At the moment the only drug for obesity on the market in Europe is Roche's Xenical (orlistat), a lipase inhibitor that has been available ...

as a drug with the same active ingredient known as Saxenda was released later. The generic version of Victoza, developed by UK Hikma Pharmaceuticals, is set to be launched across the United States ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

The approval is for the generic versions of Victoza to treat Type-2 Diabetes and Saxenda used in the treatment of weight management It can be used for medicines that do not need to be authorised via ...

Saxenda continues to develop a dominant position in obesity pharmacotherapy however, and Novo Nordisk said the drug currently has a market share of 63% worldwide.

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

The approval covers generic versions of two Novo Nordisk products: Victoza, used in the treatment of Type-2 Diabetes, and Saxenda, which is indicated for weight management. This marks a ...